On December 13, 2023, the National Health Insurance Bureau and the Ministry of Human Resources and Social Security announced the "National Drug List for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (2023)", and the oral dosage form of Nuzyra ® (omadacycline mesylate), exclusively promoted by HanHui Pharma (a wholly owned subsidiary of HaiZheng Pharmaceuticals) in mainland China and the product of Zaidin Pharmaceuticals, has successfully been included in the 2023 edition of the National Health Insurance The oral dosage form of Nuzyra ® (omadacycline mesylate), a product of Zaidin Pharmaceuticals, has been successfully included in the 2023 edition of the National Health Insurance Drug Catalog, which will be formally implemented on January 1, 2024

Mr. Shen Xinghu, Secretary of the Party Committee and Chairman of the Board of Directors of Haizheng Pharmaceutical, said: Haizheng Pharmaceutical is committed to building HANHUI into an industry-leading pharmaceutical enterprise integrating research, production and marketing, focusing on the specialized promotion of domestic and foreign innovative drugs and original drugs to meet the unmet clinical needs. After two years on the market, Nuzyra injection and oral dosage form have been included in the National Health Insurance Catalog, which is a significant achievement of HANHUI in the clinical promotion of high-clinical-value products; at the same time, the inclusion of Nuzyra in the Health Insurance will further improve the accessibility of Nuzyra and benefit more Chinese patients.

As a national Class 1 new drug approved by the State Drug Administration in December 2021, Nuzyra is the only third-generation tetracycline with both oral and intravenous dosage forms. It possesses broad-spectrum antimicrobial activity, with good bacteriostatic effects against common gram-positive, gram-negative, atypical pathogens, and anaerobic bacteria, etc., and is used for the treatment of Community Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Thanks to its novel drug structure, Nuzyra overcomes the resistance of pathogenic microorganisms such as bacteria to existing tetracyclines. After nearly two years of clinical application, its efficacy and safety have been widely recognized by clinicians and patients.

Huizheng Pharmaceutical Ltd., a wholly-owned subsidiary of Hanhui Pharmaceuticals, was granted the exclusive right to promote Nuzyra in Mainland China in March 2020. The injectable dosage form of Nuzyra has been entered into the National Health Insurance Catalog in January 2023 and will be implemented on March 1, 2023. HANHUI PHARMACEUTICAL has always taken the responsibility of carrying out compliant, professional and efficient academic promotion, building an all-round academic exchange platform for various fields, and practicing the mission of "wholeheartedly guarding the healthy life of the nation".

https://mp.weixin.qq.com/s/YStfHWzFCTxqp90oyeaeQQ